Q1 2019 EPS Estimates for Teleflex Incorporated Decreased by Piper Jaffray Companies (TFX)

Teleflex Incorporated (NYSE:TFX) – Analysts at Piper Jaffray Companies decreased their Q1 2019 EPS estimates for Teleflex in a research note issued on Thursday, February 21st. Piper Jaffray Companies analyst M. O’brien now anticipates that the medical technology company will post earnings per share of $2.48 for the quarter, down from their prior forecast of $2.52. Piper Jaffray Companies has a “Overweight” rating and a $310.00 price objective on the stock. Piper Jaffray Companies also issued estimates for Teleflex’s Q2 2019 earnings at $2.70 EPS, Q1 2020 earnings at $2.77 EPS, Q2 2020 earnings at $3.03 EPS, Q3 2020 earnings at $3.14 EPS, Q4 2020 earnings at $3.51 EPS and FY2021 earnings at $14.50 EPS.

Teleflex (NYSE:TFX) last released its earnings results on Thursday, February 21st. The medical technology company reported $2.77 earnings per share for the quarter, topping the Zacks’ consensus estimate of $2.76 by $0.01. The firm had revenue of $641.60 million during the quarter, compared to analyst estimates of $641.06 million. Teleflex had a net margin of 2.81% and a return on equity of 18.04%. The business’s revenue was up 7.8% on a year-over-year basis. During the same quarter in the previous year, the business earned $2.44 EPS.

TFX has been the subject of a number of other research reports. UBS Group assumed coverage on shares of Teleflex in a research report on Tuesday, November 27th. They set a “buy” rating and a $310.00 price objective for the company. Needham & Company LLC reaffirmed a “buy” rating and set a $315.00 price objective on shares of Teleflex in a research report on Friday, November 2nd. Morgan Stanley upped their price objective on shares of Teleflex from $295.00 to $305.00 and gave the company an “overweight” rating in a research report on Wednesday, January 2nd. Finally, TheStreet raised shares of Teleflex from a “c+” rating to a “b-” rating in a research report on Wednesday, November 28th. Three analysts have rated the stock with a hold rating and six have given a buy rating to the stock. The stock has a consensus rating of “Buy” and a consensus target price of $291.88.

Shares of TFX opened at $275.23 on Friday. The stock has a market cap of $13.17 billion, a PE ratio of 32.77, a P/E/G ratio of 2.07 and a beta of 1.08. The company has a debt-to-equity ratio of 0.83, a current ratio of 2.26 and a quick ratio of 1.51. Teleflex has a 52 week low of $226.02 and a 52 week high of $287.59.

A number of hedge funds and other institutional investors have recently bought and sold shares of TFX. Bank of New York Mellon Corp grew its stake in Teleflex by 0.3% during the second quarter. Bank of New York Mellon Corp now owns 548,319 shares of the medical technology company’s stock worth $147,064,000 after buying an additional 1,783 shares during the last quarter. First Hawaiian Bank bought a new stake in Teleflex during the third quarter worth about $156,000. Aperio Group LLC grew its stake in Teleflex by 5.2% during the third quarter. Aperio Group LLC now owns 14,874 shares of the medical technology company’s stock worth $3,958,000 after buying an additional 740 shares during the last quarter. IFM Investors Pty Ltd grew its stake in Teleflex by 14.5% during the third quarter. IFM Investors Pty Ltd now owns 2,524 shares of the medical technology company’s stock worth $672,000 after buying an additional 319 shares during the last quarter. Finally, Xact Kapitalforvaltning AB grew its stake in Teleflex by 7.3% during the third quarter. Xact Kapitalforvaltning AB now owns 6,098 shares of the medical technology company’s stock worth $1,623,000 after buying an additional 415 shares during the last quarter. 91.64% of the stock is currently owned by institutional investors and hedge funds.

In related news, insider Thomas E. Powell sold 5,200 shares of the company’s stock in a transaction dated Friday, December 7th. The shares were sold at an average price of $259.41, for a total value of $1,348,932.00. Following the sale, the insider now owns 13,651 shares of the company’s stock, valued at $3,541,205.91. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, CFO Thomas E. Powell sold 5,324 shares of the company’s stock in a transaction dated Thursday, December 27th. The shares were sold at an average price of $242.25, for a total transaction of $1,289,739.00. Following the completion of the sale, the chief financial officer now directly owns 13,775 shares in the company, valued at approximately $3,336,993.75. The disclosure for this sale can be found here. In the last three months, insiders sold 15,948 shares of company stock worth $3,952,433. 2.56% of the stock is currently owned by insiders.

The firm also recently announced a dividend, which will be paid on Friday, March 15th. Investors of record on Friday, March 1st will be paid a $0.34 dividend. The ex-dividend date of this dividend is Thursday, February 28th. Teleflex’s payout ratio is currently 16.19%.

Teleflex Company Profile

Teleflex Incorporated designs, develops, manufactures, and supplies single-use medical devices for common diagnostic and therapeutic procedures in critical care and surgical applications worldwide. It offers vascular access products that comprise Arrow branded catheters and related devices, including catheter positioning systems for use in the administration of intravenous medications and other therapies, the measurement of blood pressure, and the withdrawal of blood samples through a single puncture site; and devices for treating coronary and peripheral vascular disease.

Recommended Story: How does inflation affect different investments?

Earnings History and Estimates for Teleflex (NYSE:TFX)

Receive News & Ratings for Teleflex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teleflex and related companies with MarketBeat.com's FREE daily email newsletter.



Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit